This page shows the latest UCB Pharma news and features for those working in and with pharma, biotech and healthcare.
Like the Handl acquisition, UCB did not offer the financial details of the Lacerta research collaboration and licensing agreement. ... The Handl and Lacerta deals build on UCB’s previous acquisition of Element Genomics in 2018.
CEO outlines pipeline promise, won't write off post-Brexit UK. Mid-sized pharma company UCB has seen its epilepsy treatment Vimpat break through the $1bn+ annual revenues mark, joining its ... Jean-Christophe Tellier. Speaking to Pharma Market Europe
Company and academic researchers to share one facility. UCB Pharma has boosted its R&D capabilities in the UK by signing a new 3-year collaboration with King’s College London ... UCB researchers will share labs with academics from KCL at Guy’s Campus
Meanwhile, Aurora Healthcare Communications’ Travel with IBD campaign for Japanese pharma group Takeda and charity Crohn’s &Colitis UK won an award in the Excellence in Healthcare Collaboration and Partnerships category. ... The internal campaign
Act on Fractures (frACTure) – World Osteoporosis Day 2017 by Chamberlain Healthcare PR, a Syneos Health Company, for UCB Pharma.
Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools. ... Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more.
More from news
Approximately 3 fully matching, plus 82 partially matching documents found.
Clough says UCB is a role model for how pharma should approach digital health. ... UCB has stuck with it, putting the right team in place to see an end-to-end solution come to fruition - something that pharma doesn’t usually do.
Like many of the big pharmaceutical players, UCB is riding out from its well-appointed laboratories and gleaming head office corrals to prospect for pharma gold. ... Increase returns. UCB is one of the partners in a consortium that includes other EFPIA
For an indepth analysis of these deals, read'Pharma deals during November 2014'. ... UCB (Kremers Urban Pharma) /Advent International and Avista Capital Partners. Generics portfolio.
I think that one of the main challenges of the pharma industry is not being terribly efficient. ... innovation approach to finding future treatments in key for UCB areas, such as neurology and autoimmue disorders.
Another deal which featured an option this month is Leo Pharma's option to license 4SC Discovery's pre-clinical product for psoriasis. ... UCB Pharma [but not GSK]) pooling its research efforts with academics (in UK, Germany and Netherland) and SMEs in a
More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.
He has also held roles at UCB Pharma and 3M in Italy.
Steve Turley joins from Lundbeck. UCB have appointed Steve Turley as managing director for the British and Irish isles. ... Turley will also be an important figure in UCB's European Leadership Team and will report to Khoso Baluch, head of EMEA Operations.
Roch Doliveux, who retired as CEO of UCB at the end of 2014. ... The IMI is a public-private partnership between the European Union and European pharma body EFPIA and its governing board is the IMI's main decision-making body.
Tellier was elected by member of the European Medicines Group (EMG) and will act as group representative for the European pharma companies. ... Tellier joined UCB in 2011 as an executive VP after serving as president of Ipsen, North America, and CEO of
Dr Sachse was most recently head of global translational medicine at Germany-based Boehringer following several roles at major pharma companies in Europe, including Bayer, Schwarz Pharma and UCB.
More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.
Mylan, Novartis, Orphan Europe, Philips, Pfizer, Roche, Sanofi, Takeda, UCB, Uriach, Vifor Pharma. ... See how three pharma companies supported the provision of virtual and on-demand scientific meetings for HCPs during COVID-19.
Pharma companies are entering risk-sharing agreements in order to achieve higher reimbursement. ... So far UCB is the only pharma company who has engaged in a risk-sharing agreement with payer.
Top pharma minds including C-Level executives from Boehringer Ingelheim, Baxter, Janssen and UCB, together with a range of notable academics and stakeholders, make up the panel. ... Adding to this sentiment, judge Lode Dewulf, Chief Patient Officer at
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...